Clearance of normal and type 2A von Willebrand factor in the rat

Blood

Volumn 88, Issue 5, 1996, Pages 1692-1699

  Stoddart Jr , John H ^a   Andersen, Janet ^a   Lynch, Dennis C ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACRYLAMIDE; APROTININ; BENZAMIDINE; BENZYLSULFONYL FLUORIDE; EDETIC ACID; LEUPEPTIN; N ETHYLMALEIMIDE; N,N' METHYLENEBISACRYLAMIDE; POLYMER; PROTEINASE INHIBITOR; VON WILLEBRAND FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG DESIGN; ENDOTHELIUM CELL; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; UMBILICAL VEIN; VON WILLEBRAND DISEASE;

EID: 0029792263     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.5.1692.bloodjournal8851692     Document Type: Article

References (34)

1. Wagner DD: Cell Biology of von Willebrand factor. Annu Rev Cell Biol 6:217, 1990
2. Ruggeri ZM, Zimmerman TS: von Willebrand Factor and von Willebrand disease. Blood 70:895, 1987
3. Jaffe EA, Hoyer LW, Nachman RL: Synthesis of antihemophilic factor antigen by cultured human endothelial cells. J Clin Invest 52:2757, 1973
4. Wagner DD, Marder VJ: Biosynthesis of von Willebrand protein by human endothelial cells: Processing steps and their intracellular localization. J Cell Biol 99:2123, 1984
5. Marti T, Rosselet SJ, Titani, K, Walsh KA: Identification of disulfide-bridged substructures within human von Willebrand factor. Biochemistry 26:8099, 1987
6. Fretto LJ, Fowler WE, McCaslin DR, Erickson HP, McKee PA: Substructure of human von Willebrand factor: Proteolysis by V8 and characterization of two functional domains. J Biol Chem 261:15679, 1986
7. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, Ashida K, Walsh KA, Chopek MW, Sadler EJ, Fujikawa K: Amino acid sequence of human von Willebrand factor. Biochemistry 25:3171, 1986
8. Carew JA, Browning PJ, Lynch DC: Sulfation of von Willebrand Factor. Blood 76:2530, 1990
9. Rodeghiero F, Castaman G, Dini E: Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 69:454, 1987
10. Lynch DC: Molecular genetics of von Willebrand disease, in Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ (eds): Hematology: Basic Principles and Practice. New York, NY, Churchill Livingstone, 1991, p 1359
11. Zimmerman TS, Dent JA, Ruggeri ZM, Nannini LH: Subunit composition of plasma von Willebrand Factor. J Clin Invest 77:947, 1986
12. Carew JA, Quinn SM, Stoddart JH, Lynch DC: O-Linked carbohydrate of recombinant von Willebrand Factor influences ristocetin-induced binding to platelet glycoprotein IB. J Clin Invest 90:2258, 1992
13. Chang, H-Y, Chen, YP, Chediak JR, Levene RB, Lynch DC: Molecular analysis of von Willebrand Factor produced by endothelial cell strains from patients with type 2A von Willebrand disease. Blood 74:482a, 1989 (abstr, suppl 1)
14. Levene RB, Booyse FM, Chediak J, Zimmerman TS, Livingston DM, Lynch DC: Expression of abnormal von Willebrand Factor by endothelial cells from a patient with type 2A von Willebrand disease. Proc Natl Acad Sci USA 84:6550, 1987
15. Kingsley DM, Kozarski KF, Hobbie L, Krieger M: Reversible defects in O-linked glycosylation and LDL receptor expression in a UDP-Gal/UDP-GalNac 4-epimerase deficient mutant. Cell 44:749, 1986
16. Felgner PL, Gadek TR, Holm M, Rodman R, Chan WH, Wenz M, Danielsen M: Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84:7413, 1987
17. Upton RA: Simple and reliable method for serial sampling of blood from rats. J Pharm Sci 64:112, 1975
18. Lynch DC, Zimmerman TS, Kirby EP, Livingston DM: Subunit composition of oligomeric von Willebrand Factor. J Biol Chem 258:12757, 1983
19. Gibaldi M: Biopharmaceutics and Clinical Pharmacokinetics, (ed 3). Philadelphia, PA, Lea & Febiger, 1991
20. Fiete D, Srivastava V, Hindsgaul O, Baenziger JU: A Hepatic reticuloendothelial cell receptor specific for SO4-4GalNAcB1,4Glc-NAcB1,2Mana that mediates rapid clearance of lutropin. Cell 67:1103, 1991
21. Leyte A, van Schijndel, HB, Niehrs C, Huttner WB, Verbeet MP, Mertens K, van Mourik JA: Sulfation of Tyr (1680) of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 266:740, 1991
22. Emmanouel DS, Goldwasser E, Katz AI: Metabolism of pure human erythropoetin in the rat. Am J Physiol 247:168, 1984
23. Steinberg SE, Garcia JF, Matzke GR, Mladeonovic J: Erythropoetin kinetics in rats: Generation and clearance. Blood 67:646, 1986
24. Sodetz JM, Pizzo S, McKee P: Relationship of sialic acid to function and in vivo survival of human Factor VIII/von Willebrand Factor protein. J Biol Chem 252:5538, 1977
25. Dent JA, Galbusera M, Ruggeri ZM: Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit. J Clin Invest 88:74, 1991
26. Dent JA, Berkowitz SD, Ware J, Kasper CK, Ruggeri ZM: Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type 2A von Willebrand Factor. Proc Natl Acad Sci USA 87:6306, 1990
27. Battle, J, Lopez-Fernandez MF, Campos M, Justica B, Berges C, Navarro JL, Diaz-Cremades J, Kasper CK, Dent JA, Ruggeri ZM, Zimmerman TS: The heterogeneity of type 2A von Willebrand's disease: Studies with protease inhibitors. Blood 68:1207, 1986
28. Morell AG, Gregoriadis G, Scheinber H, Hickman J, Ashwell G: The role of sialic acid in determining the survival of glycoproteins in the circulation. J Biol Chem 246:1461, 1971
29. Spivak JL, Hogan BB: The in vivo metabolism of recombinant human erythropoetin in the rat. Blood 73:90, 1989
30. Ashwell G, Harford J: Carbohydrate-specific receptors of the liver. Annu Rev Biochem 51:531, 1982
31. Baenziger JU, Kumar S, Brodbeck RM, Smith PL, Beranek MC: Circulatory half-life but not interaction with the lutropin/chorionic gonadotropic receptor is modulated by sulfation of bovine lutropin oligosaccharides. Proc Natl Acad Sci USA 89:334, 1992
32. Chediak JR, Telfer MC, Green D: Platelet function and immunologic parameters in von Willebrand's disease following cryoprecipitate and factor VIII concentrate infusion. Am J Med 62:369, 1977
33. Over J, Sixma JJ, Bouma BN, Bolhuis PA, Vlooswijk RA, Beeser-Visser NH: Survival of iodine-125-labeled factor VIII in patients with von Willebrand's disease. J Lab Clin Med 97:332, 1981
34. Pasi KJ, Williams MD, Enayat, MS, Hill FG: Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat-treated factor VIII concentrate (BPL 8Y). Br J Haematol 75:228, 1990